Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics reports developments in genomic medicine, with a pipeline centered on neurological diseases, Fabry disease gene therapy, zinc finger epigenetic regulation, capsid discovery and modular integrase technology. Company updates commonly cover clinical and nonclinical data presentations, regulatory submissions for isaralgagene civaparvovec, or ST-920, in Fabry disease, and neurology programs such as small fiber neuropathy and chronic neuropathic pain.
Recurring news also includes financial results, earnings calls, collaboration and licensing activity around neurotropic capsids, and public-company matters affecting SGMO common stock. Listing-status announcements, including Nasdaq compliance and OTCQB quotation matters, form part of the company's corporate-status coverage alongside pipeline and technology updates.
Sangamo Therapeutics reported Q3 2020 financial results, showing revenues of $57.8 million, up from $22.0 million in Q3 2019. The company achieved a $30 million milestone from Pfizer for dosing the first patient in the Phase 3 AFFINE study for hemophilia A gene therapy. Cash and equivalents increased to $694.6 million. Despite a net loss of $1.6 million (or $0.01 per share), down from a loss of $27.3 million in the prior year, operating expenses rose to $61.5 million. The company revised its operating expense guidance for 2020 to $210 to $220 million.
Sangamo Therapeutics (Nasdaq: SGMO) has announced the release date for its third quarter 2020 financial results, set for November 4, 2020, after market close. A conference call will follow at 5:00 p.m. ET, where financial results and business updates will be discussed. Interested participants can join via telephone or webcast, with specific dial-in numbers provided for domestic and international callers. A replay of the conference call will be available for one week thereafter.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced its participation in two upcoming investor conferences. The Jefferies Virtual Gene Therapy / Editing Summit will take place on October 1st at 12:00 PM ET, followed by the Chardan Genetic Medicines Conference on October 5th at 8:00 AM ET. Both presentations will be webcast live and accessible via the Sangamo website's Investors and Media section. The company's focus is on developing genomic medicines, including gene therapy and genome editing.